BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15765234)

  • 1. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.
    Breeuwsma AJ; Pruim J; Jongen MM; Suurmeijer AJ; Vaalburg W; Nijman RJ; de Jong IJ
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):668-73. PubMed ID: 15765234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
    Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.
    Giovacchini G; Picchio M; Coradeschi E; Scattoni V; Bettinardi V; Cozzarini C; Freschi M; Fazio F; Messa C
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1065-73. PubMed ID: 18200444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging prostate cancer with 11C-choline PET/CT.
    Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
    J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
    Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ROLE OF KINETIC PERFORMANCE OF PSA IN SELECTION OF THE PATIENTS FOR CONDUCTION OF 11C-CHOLINE PET/CT AIMED TO REVEAL LOCAL RECURRENCES OF PROSTATE CANCER].
    Rybalov MA; De Iong IY; Breusma AI; Al'-Shukri SKh; Borovets SY
    Vestn Khir Im I I Grek; 2015; 174(6):25-8. PubMed ID: 27066654
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Grkovski M; Gharzeddine K; Sawan P; Schöder H; Michaud L; Weber WA; Humm JL
    J Nucl Med; 2018 Nov; 59(11):1672-1678. PubMed ID: 29626123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
    Yoshida S; Nakagomi K; Goto S; Futatsubashi M; Torizuka T
    Urol Int; 2005; 74(3):214-20. PubMed ID: 15812206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.
    Piert M; Park H; Khan A; Siddiqui J; Hussain H; Chenevert T; Wood D; Johnson T; Shah RB; Meyer C
    J Nucl Med; 2009 Oct; 50(10):1585-93. PubMed ID: 19759109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.
    Souvatzoglou M; Weirich G; Schwarzenboeck S; Maurer T; Schuster T; Bundschuh RA; Eiber M; Herrmann K; Kuebler H; Wester HJ; Hoefler H; Gschwend J; Schwaiger M; Treiber U; Krause BJ
    Clin Cancer Res; 2011 Jun; 17(11):3751-9. PubMed ID: 21493868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.
    Reske SN; Blumstein NM; Glatting G
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):9-17. PubMed ID: 17828534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
    Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
    J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.